title: Antidepressant effect on connectivity of the mood-regulating circuit: an FMRI study.
abstract: The mechanisms by which antidepressant-induced neurochemical changes lead to physiological changes in brain circuitry and ultimately an antidepressant response remain unclear. This study investigated the effects of sertraline, a selective serotonin reuptake inhibitor antidepressant, on corticolimbic connectivity, using functional magnetic resonance imaging (fMRI). In all, 12 unmedicated unipolar depressed patients and 11 closely matched healthy control subjects completed two fMRI scanning sessions at baseline and after 6 weeks. Depressed patients received treatment with sertraline between the two sessions. During each fMRI session, subjects first completed a conventional block-design experiment. Next, connectivity between cortical and limbic regions was measured using correlations of low-frequency blood oxygen level-dependent (BOLD) fluctuations (LFBF) during continuous exposure to neutral, positive, and negative pictures. At baseline, depressed patients had decreased corticolimbic LFBF correlations compared to healthy subjects during the resting state and on exposure to emotionally valenced pictures. At rest and on exposure to neutral and positive pictures, LFBF correlation between the anterior cingulate cortex and limbic regions was significantly increased in patients after treatment. However, on exposure to negative pictures, corticolimbic LFBF correlations remained decreased in depressed patients. The results of this study are consistent with the hypothesis that antidepressant treatment may increase corticolimbic connectivity, thereby possibly increasing the regulatory influence of cortical mood-regulating regions over limbic regions.
authors.affiliation: Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN 46202, USA. aanand@iupui.edu
authors.forename: Amit
authors.initials: A
authors.lastname: Anand
authors.forename: Yu
authors.initials: Y
authors.lastname: Li
authors.forename: Yang
authors.initials: Y
authors.lastname: Wang
authors.forename: Jingwei
authors.initials: J
authors.lastname: Wu
authors.forename: Sujuan
authors.initials: S
authors.lastname: Gao
authors.forename: Lubna
authors.initials: L
authors.lastname: Bukhari
authors.forename: Vincent P
authors.initials: VP
authors.lastname: Mathews
authors.forename: Andrew
authors.initials: A
authors.lastname: Kalnin
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Lowe
mesh_terms: D000328:Adult; D000339:Affect / Q000187:drug effects* / Q000502:physiology; D000928:Antidepressive Agents / Q000008:administration & dosage*; D001921:Brain / Q000098:blood supply / Q000473:pathology; D001931:Brain Mapping; D016022:Case-Control Studies; D003863:Depression / Q000188:drug therapy / Q000378:metabolism*; D004644:Emotions / Q000502:physiology; D005149:Facial Expression; D005260:Female; D006801:Humans; D007091:Image Processing, Computer-Assisted; D016014:Linear Models; D008279:Magnetic Resonance Imaging; D008297:Male; D009434:Neural Pathways / Q000098:blood supply / Q000187:drug effects / Q000473:pathology; D010100:Oxygen / Q000097:blood; D010775:Photic Stimulation / Q000379:methods; D020280:Sertraline / Q000008:administration & dosage*
chemical_list: D000928:Antidepressive Agents; D020280:Sertraline; D010100:Oxygen